A2 Refereed review article in a scientific journal
New tools to prevent cancer growth and spread: a 'Clever' approach
Authors: Maija Hollmén, Carlos R. Figueiredo, Sirpa Jalkanen
Publisher: NATURE PUBLISHING GROUP
Publication year: 2020
Journal: British Journal of Cancer
Journal name in source: BRITISH JOURNAL OF CANCER
Journal acronym: BRIT J CANCER
Volume: 123
Issue: 4
First page : 501
Last page: 509
Number of pages: 9
ISSN: 0007-0920
eISSN: 1532-1827
DOI: https://doi.org/10.1038/s41416-020-0953-0
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/48818005
Clever-1 (also known as Stabilin-1 and FEEL-1) is a scavenger receptor expressed on lymphatic endothelial cells, sinusoidal endothelial cells and immunosuppressive monocytes and macrophages. Its role in cancer growth and spread first became evident inStab1(-/-)knockout mice, which have smaller primary tumours and metastases. Subsequent studies in mice and humans have shown that immunotherapeutic blockade of Clever-1 can activate T-cell responses, and that this response is mainly mediated by a phenotypic change in macrophages and monocytes from immunosuppressive to pro-inflammatory following Clever-1 inhibition. Analyses of human cancer cohorts have revealed marked associations between the number of Clever-1-positive macrophages and patient outcome. As hardly any reports to date have addressed the role of Clever-1 in immunotherapy resistance and T-cell dysfunction, we performed data mining using several published cancer cohorts, and observed a remarkable correlation between Clever-1 positivity and resistance to immune checkpoint therapies. This result provides impetus and potential for the ongoing clinical trial targeting Clever-1 in solid tumours, which has so far shown a shift towards immune activation when a particular epitope of Clever-1 is blocked.
Downloadable publication This is an electronic reprint of the original article. |  |
